Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights and Director/PDMR Shareholding

21 Nov 2018 11:00

RNS Number : 0841I
Frontier IP Group plc
21 November 2018
 

21 November 2018

 

Frontier IP Group plc

("Frontier IP" or the "Company")

 

Total Voting Rights and Director/PDMR Shareholdings

 

Frontier IP, which specialises in commercialising university intellectual property, announces that the 3,827,852 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") issued pursuant to the placing announced on 15 November 2018 (the "Placing") have today been admitted to trading on AIM ("Admission") and the Placing has completed. The Company's issued share capital now consists of 42,106,372 Ordinary Shares with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 42,106,372.

 

This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Director/PDMR Shareholdings

 

Michael Bourne, Non-Executive Director of the Company, subscribed for 32,932 Ordinary Shares in the Placing at a price of 65 pence per share and now holds a total interest in 303,170 Ordinary Shares, equivalent to 0.72 per cent. of the Company's enlarged ordinary share capital. Details of this purchase were included in the announcement on 15 November 2018.

 

Following Admission, the Directors' beneficial shareholdings are as follows:

 

 

Director

Interest in Ordinary Shares upon Admission

Percentage of voting rights in the Company upon Admission

Andrew Richmond (Non-executive Chairman)

1,000,000

2.37

Neil Crabb (Chief Executive Officer)

2,834,168

6.73

James Fish (Finance Director)

100,000

0.23

Jacqueline McKay (Chief Operating Officer)

12,855

0.03

David Cairns (Portfolio Director)

840,238

1.99

Michael Bourne (Non-executive Director)

303,170

0.72

Campbell Wilson (Non-executive Director)

-

-

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Bourne

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

65.00p

32,932

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

21 November 2018

f)

Place of the transaction

Outside a Trading Venue - placing of new ordinary shares

 

The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

Enquiries:

Frontier IP Group plc

T: 0131 240 1251

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

M: 07464 546 025

www.frontierip.co.uk

 

 

 

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

 

Amrit Nahal (Equity Sales)

 

Notes to Editors:

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. The group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKMMZMGMDGRZM
Date   Source Headline
15th Nov 201810:05 amRNSExscientia acquires Kinetic Discovery
15th Nov 20189:30 amRNSPlacing to raise £2.49 million
15th Nov 20189:25 amRNSFinal Results
30th Oct 20187:00 amRNSSecond Portuguese spin out: Des Solutio
19th Oct 20187:00 amRNSMolendotech signs collaboration agreement with G's
5th Oct 20187:00 amRNSDIT hails Frontier IP's Portuguese success
27th Sep 20187:00 amRNSChange of Adviser
26th Sep 20185:12 pmRNSDirector Declaration
24th Sep 20182:30 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSAmprologix to develop new antibiotics with Ingenza
18th Sep 20181:56 pmRNSAlusid raises £1.34m to scale up manufacturing
17th Sep 20187:00 amRNSAB Sugar Head of Innovation joins Frontier IP
30th Aug 201812:39 pmRNSHolding(s) in Company
15th Aug 20187:00 amRNSTVG awarded £50,000 anti-bacterial vaccine grant
7th Aug 20187:00 amRNSPortfolio news - first Portuguese spin out
6th Aug 20187:00 amRNSFieldwork Robotics agreement with Hall Hunter
2nd Aug 20187:00 amRNSFrontier IP partners with UK DIT in Portugal
16th Jul 20187:00 amRNSTarsis Collaboration with Crop-Protection Company
11th Jul 20187:00 amRNSInnovate UK grant for Pulsiv Solar
19th Jun 20187:00 amRNSCambridge Material Testing Solutions
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics
27th Mar 20187:00 amRNSHALF-YEAR RESULTS, 6 MONTHS TO 31 DECEMBER 2017
26th Mar 20187:00 amRNSTeam Expansion and London Office
19th Feb 20187:00 amRNSPortfolio News - Molendotech Secures First Funding
29th Jan 20187:00 amRNSCapital Markets Day
29th Jan 20187:00 amRNSPortfolio News - Molendotech Collaboration
18th Dec 20177:00 amRNSCapital Markets Day
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration
30th Mar 20177:00 amRNSHalf-Year Results for the 6 Months to 31 Dec 2016
24th Mar 20174:33 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.